Literature DB >> 33175289

Extracellular matrix collagen biomarkers levels in patients with chronic thromboembolic pulmonary hypertension.

Wenyi Pang1,2,3, Zhu Zhang1,2,3, Yunxia Zhang1,2, Meng Zhang1,2, Ran Miao4,5, Yuanhua Yang4,5, Wanmu Xie1,2,5, Jun Wan1,2,5, Zhenguo Zhai6,7,8,9, Chen Wang1,2,3,5.   

Abstract

Limited data exist on changes in the extracellular matrix (ECM) collagen biomarkers levels during chronic thromboembolic pulmonary hypertension (CTEPH) development. This study aimed to investigate ECM collagen biomarkers levels in stable patients with CTEPH. Patients with CTEPH and healthy persons were enrolled. Serum levels of procollagen III N-terminal peptide (PIIINP), carboxyterminal propeptide of type I procollagen (PICP), matrix metalloproteinases (MMP2), MMP9, and tissue inhibitor of metalloproteinases 1(TIMP1) were measured by ELISA. Clinical data coincident with samples were collected. The pulmonary endarterectomy (PEA) and control pulmonary artery tissue samples were analyzed for genetic and immunohistochemical differences. The serum concentrations of PIIINP, PICP, MMP2, and MMP9 decreased significantly in CTEPH patients compared to healthy controls (P < 0.001 for each). CTEPH patients had higher serum concentrations of TIMP1 (median, 111.97 [interquartile range, 84.35-139.93]) compared to healthy controls (74.97 [44.03-108.45] ng/mL, P < 0.001). The MMP2 to TIMP1 ratio was lower in patients than in the controls (P < 0.001). After adjusting for the body mass index (BMI), the MMP2 to TIMP1 ratio correlated negatively with pulmonary vascular resistance (PVR) (r = - 0.327, P = 0.025). Increased TIMP1 (P = 0.04) gene expression was identified in tissues of CTEPH patients. Immunohistochemistry results of vascular walls substantiated qRT-PCR results. This study indicates that ECM collagen biomarkers levels were significantly different in stable patients with CTEPH and healthy controls with significantly increased TIMP1 and decreased MMP2 and MMP9. Differences in TIMP1 expression should be expected not only among healthy controls and patients serum, but also across pathological tissue regions. These findings suggest that the state of vascular remodeling in pulmonary vascular bed in stable patients may be represented by ECM collagen biomarkers levels. We conclude that TIMP1 may play an important role in pulmonary vascular reconstruction in stable CTEPH patients.
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Chronic thromboembolic pulmonary hypertension; Extracellular matrix; Matrix metalloproteinases; Tissue inhibitor of metalloproteinases

Mesh:

Substances:

Year:  2020        PMID: 33175289     DOI: 10.1007/s11239-020-02329-8

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  28 in total

1.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Respir J       Date:  2015-08-29       Impact factor: 16.671

2.  Pulmonary arterial strain- and remodeling-induced stiffening are differentiated in a chronic model of pulmonary hypertension.

Authors:  Mark J Golob; Diana M Tabima; Gregory D Wolf; James L Johnston; Omid Forouzan; Ashley M Mulchrone; Heidi B Kellihan; Melissa L Bates; Naomi C Chesler
Journal:  J Biomech       Date:  2017-02-21       Impact factor: 2.712

3.  From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension.

Authors:  Magdalena L Bochenek; Nico S Rosinus; Mareike Lankeit; Lukas Hobohm; Felix Bremmer; Eva Schütz; Frederikus A Klok; Sven Horke; Christoph B Wiedenroth; Thomas Münzel; Irene M Lang; Eckhard Mayer; Stavros Konstantinides; Katrin Schäfer
Journal:  Thromb Haemost       Date:  2017-02-02       Impact factor: 5.249

Review 4.  Biosynthesis of procollagen.

Authors:  J H Fessler; L I Fessler
Journal:  Annu Rev Biochem       Date:  1978       Impact factor: 23.643

5.  Potential Involvement of Osteopontin in Inflammatory and Fibrotic Processes in Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Sebastian Kölmel; Lukas Hobohm; Anja Käberich; Valentin J Krieg; Magdalena L Bochenek; Philip Wenzel; Christoph B Wiedenroth; Christoph Liebetrau; Gerd Hasenfuß; Eckhard Mayer; Stavros V Konstantinides; Katrin Schäfer; Stefan Guth; Mareike Lankeit
Journal:  Thromb Haemost       Date:  2019-06-10       Impact factor: 5.249

6.  Collagen biomarkers are associated with decline in renal function independently of blood pressure and other cardiovascular risk factors: the Multi-Ethnic Study of Atherosclerosis Study.

Authors:  Daniel A Duprez; Myron D Gross; Joachim H Ix; Carmen A Peralta; Jorge R Kizer; Steven Shea; David R Jacobs
Journal:  J Hypertens       Date:  2019-12       Impact factor: 4.844

7.  TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms.

Authors:  Takemi Akahane; Manabu Akahane; Amy Shah; Christine M Connor; Unnur P Thorgeirsson
Journal:  Exp Cell Res       Date:  2004-12-10       Impact factor: 3.905

8.  Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.

Authors:  Wafae Iraqi; Patrick Rossignol; Michael Angioi; Renaud Fay; Josette Nuée; Jean Marie Ketelslegers; John Vincent; Bertram Pitt; Faiez Zannad
Journal:  Circulation       Date:  2009-04-27       Impact factor: 29.690

9.  Tissue inhibitor of metalloproteinase-3 deficiency inhibits blood pressure elevation and myocardial microvascular remodeling induced by chronic administration of Nomega-nitro-L-arginine methyl ester in mice.

Authors:  Masayoshi Higuchi; Osamu Yasuda; Hidenobu Kawamoto; Takamori Yotsui; Yoshichika Baba; Tohru Ozaki; Nobuyo Maeda; Keisuke Fukuo; Hiromi Rakugi; Toshio Ogihara
Journal:  Hypertens Res       Date:  2007-06       Impact factor: 3.872

10.  The role of matrix metalloproteinase in the intimal sarcoma-like cells derived from endarterectomized tissues from a chronic thromboembolic pulmonary hypertension patient.

Authors:  Takayuki Jujo; Seiichiro Sakao; Masanori Tsukahara; Masashi Kantake; Seiji Kantake; Miki Maruoka; Nobuhiro Tanabe; Masahisa Masuda; Koichiro Tatsumi
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

View more
  5 in total

Review 1.  Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies.

Authors:  Helen Christou; Raouf A Khalil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-02-25       Impact factor: 4.733

Review 2.  Targeting the cytoskeleton and extracellular matrix in cardiovascular disease drug discovery.

Authors:  Bohdan B Khomtchouk; Yoon Seo Lee; Maha L Khan; Patrick Sun; Deniel Mero; Michael H Davidson
Journal:  Expert Opin Drug Discov       Date:  2022-03-08       Impact factor: 7.050

Review 3.  Exploring Functional Differences between the Right and Left Ventricles to Better Understand Right Ventricular Dysfunction.

Authors:  Judith Bernal-Ramirez; Magda C Díaz-Vesga; Matias Talamilla; Andrea Méndez; Clara Quiroga; Javier A Garza-Cervantes; Anay Lázaro-Alfaro; Carlos Jerjes-Sanchez; Mauricio Henríquez; Gerardo García-Rivas; Zully Pedrozo
Journal:  Oxid Med Cell Longev       Date:  2021-08-28       Impact factor: 6.543

4.  Methylation-mediated silencing of PTPRD induces pulmonary hypertension by promoting pulmonary arterial smooth muscle cell migration via the PDGFRB/PLCγ1 axis.

Authors:  Junhua Xu; Yanfeng Zhong; Haoyang Yin; John Linneman; Yixuan Luo; Sijian Xia; Qinyi Xia; Lei Yang; Xingtao Huang; Kang Kang; Jun Wang; Yanqin Niu; Li Li; Deming Gou
Journal:  J Hypertens       Date:  2022-07-25       Impact factor: 4.776

Review 5.  Sex Dimorphism in Pulmonary Hypertension: The Role of the Sex Chromosomes.

Authors:  Daria S Kostyunina; Paul McLoughlin
Journal:  Antioxidants (Basel)       Date:  2021-05-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.